SCARA5

Summary

SCARA5 (scavenger receptor class A member 5, HGNC:28701) is a protein-coding gene on chromosome 8p21.1, encoding Scavenger receptor class A member 5 (Q6ZMJ2). Ferritin receptor that mediates non-transferrin-dependent delivery of iron.

Predicted to enable ferritin receptor activity. Predicted to be involved in several processes, including intracellular iron ion homeostasis; iron ion transmembrane transport; and protein homotrimerization. Predicted to act upstream of or within cellular response to heat. Predicted to be located in plasma membrane.

Source: NCBI Gene 286133 — RefSeq curated summary.

At a glance

• GWAS associations: 16
• Clinical variants (ClinVar): 83 total
• MANE Select transcript: NM_173833

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28701
Approved symbol	SCARA5
Name	scavenger receptor class A member 5
Location	8p21.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ23907, MGC45780, NET33
Ensembl gene	ENSG00000168079
Ensembl biotype	protein_coding
OMIM	611306
Entrez	286133

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 11 protein_coding

ENST00000354914, ENST00000380385, ENST00000518030, ENST00000524352, ENST00000881547, ENST00000881548, ENST00000881549, ENST00000881550, ENST00000881551, ENST00000970495, ENST00000970496

RefSeq mRNA: 4 — MANE Select: NM_173833 NM_001413201, NM_001413202, NM_001413203, NM_173833

CCDS: CCDS6064

Canonical transcript exons

ENST00000354914 — 9 exons

Exon	Start	End
ENSE00001120160	27966414	27966542
ENSE00001120161	27907148	27907246
ENSE00001159476	27909663	27909743
ENSE00001159481	27921571	27922245
ENSE00001364602	27987504	27987630
ENSE00001409681	27879569	27879766
ENSE00001424146	27904778	27904834
ENSE00001947169	27869883	27872070
ENSE00002090583	27992257	27992673

Expression profiles

Bgee: expression breadth ubiquitous, 218 present calls, max score 99.55.

FANTOM5 (CAGE): breadth broad, TPM avg 2.1329 / max 174.3292, expressed in 226 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
92519	1.2651	188
92518	0.7788	167
92517	0.0482	24
92520	0.0408	23

Top tissues by expression

248 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
decidua	UBERON:0002450	99.55	gold quality
synovial joint	UBERON:0002217	99.43	gold quality
layer of synovial tissue	UBERON:0007616	99.37	gold quality
skin of hip	UBERON:0001554	98.92	gold quality
mucosa of stomach	UBERON:0001199	98.76	gold quality
vena cava	UBERON:0004087	98.54	gold quality
upper arm skin	UBERON:0004263	98.36	gold quality
cardiac muscle of right atrium	UBERON:0003379	97.38	gold quality
pericardium	UBERON:0002407	96.84	gold quality
right coronary artery	UBERON:0001625	96.73	gold quality
upper leg skin	UBERON:0004262	96.65	gold quality
cardiac atrium	UBERON:0002081	96.10	gold quality
right atrium auricular region	UBERON:0006631	96.03	gold quality
trachea	UBERON:0003126	95.07	gold quality
tibial nerve	UBERON:0001323	94.24	gold quality
calcaneal tendon	UBERON:0003701	94.23	gold quality
coronary artery	UBERON:0001621	94.06	gold quality
urinary bladder	UBERON:0001255	93.88	gold quality
apex of heart	UBERON:0002098	93.78	gold quality
saphenous vein	UBERON:0007318	93.68	gold quality
left coronary artery	UBERON:0001626	93.65	gold quality
tibialis anterior	UBERON:0001385	93.23	silver quality
subcutaneous adipose tissue	UBERON:0002190	93.18	gold quality
adipose tissue	UBERON:0001013	93.17	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	93.09	gold quality
mammary duct	UBERON:0001765	92.95	gold quality
lower esophagus muscularis layer	UBERON:0035833	92.91	gold quality
epithelium of mammary gland	UBERON:0003244	92.87	gold quality
lower esophagus	UBERON:0013473	92.78	gold quality
urethra	UBERON:0000057	92.77	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-MTAB-6678	yes	1113.16
E-GEOD-135922	yes	61.62
E-HCAD-11	yes	41.79
E-MTAB-9543	yes	13.89
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GLI1, SNAI1

miRNA regulators (miRDB)

95 targeting SCARA5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-345-3P	99.89	70.23	1421
HSA-MIR-380-3P	99.89	70.18	1978
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-302A-3P	99.89	71.23	1777
HSA-MIR-302B-3P	99.89	71.23	1777
HSA-MIR-302C-3P	99.89	71.20	1778
HSA-MIR-302D-3P	99.89	71.25	1777
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-6079	99.84	68.54	1170
HSA-MIR-373-3P	99.84	70.68	1668
HSA-MIR-520E-3P	99.84	70.55	1698
HSA-MIR-372-3P	99.83	70.58	1691
HSA-MIR-520A-3P	99.83	70.59	1687
HSA-MIR-520B-3P	99.83	70.56	1699
HSA-MIR-520C-3P	99.83	70.56	1699

Literature-anchored findings (GeneRIF, showing 25)

• Data show that decidualization was associated with increased expression of 428 genes including SCARA5 (181-fold), DKK1 (71-fold) and PROK1 (32-fold), and decreased expression of 230 genes including MMP-7 (35-fold) and SFRP4 (21-fold). (PMID:21858178)
• Results demonstrate the involvement of SCARA3 and SCARA5 in the uptake of PF14-oligonucleotide nanocomplexes. (PMID:22138034)
• Scara5 was downregulated, pointing out this receptor as a potential player implicated in retinopathy and also as a possible therapeutic target. (PMID:25259650)
• SCARA5 and SBSN shown to have modest effects on cell proliferation or collagen gel contraction and maybe associated with peripheral vein graft patency. (PMID:25935274)
• The overexpression of SCARA5 significantly inhibited the proliferation, colony formation and migration/invasion abilities of osteosarcoma cells. (PMID:26847210)
• this study demonstrated that knockdown of SCARA5 inhibits PDGFBBinduced HASMC proliferation and migration through suppression of the PDGF signaling pathway. (PMID:27035566)
• Taken together, these results suggest that this newly identified Rock2-beta-catenin/TCF4-SCARA5 axis will provide novel insight into the understanding of the regulatory mechanisms of proliferation in human RCC. (PMID:27793664)
• The present results provide the first evidence that SCARA5 inhibits lymphangiogenesis by downregulating VEGF-C, thereby inhibiting breast cancer lymphatic metastasis. (PMID:28497372)
• The methylation status of SCARA5 gene are abnormal in Hepatocellular Carcinoma patients, which may further be used as molecular markers for early diagnosis of Liver cancer. (PMID:29019900)
• Knockdown of CSN5 increased SCARA5 expression and inhibited the proliferation and metastasis of HCC cells in vitro and in vivo. Finally, it was found that CSN5 regulated SCARA5 expression by modulating beta-catenin. (PMID:29189991)
• Scara5 has the potential to be considered as a serum biomarker in the early diagnosis of oral and squamous cell carcinoma. The clinical relevance of the study lies in finding the biomarker by proteomics and subsequently validating it with clinical samples and cell lines (PMID:29461673)
• SCARA5 may play an important role in tumorigenesis of breast cancer via promoter methylation (PMID:29908284)
• our data provide a novel evidence for the biological and clinical significance of SPAG5 as a potential biomarker, and we demonstrate that SPAG5-b-catenin-SCARA5 might be a novel pathway involved in hepatocellular carcinoma progression. (PMID:30249289)
• SCARA5 is an endocytic receptor for von Willebrand factor expressed by littoral cells in the human spleen. (PMID:31126000)
• Scavenger receptor class A, member 5 is associated with thyroid cancer cell lines progression via epithelial-mesenchymal transition. (PMID:31989658)
• SCARA5 is a Novel Biomarker in Colorectal Cancer by Comprehensive Analysis. (PMID:32658413)
• Identification of SCARA5 Gene as a Potential Immune-Related Biomarker for Triple-Negative Breast Cancer by Integrated Analysis. (PMID:32816580)
• Interactions of ferritin with scavenger receptor class A members. (PMID:32907880)
• SCARA5 suppresses the proliferation and migration, and promotes the apoptosis of human retinoblastoma cells by inhibiting the PI3K/AKT pathway. (PMID:33495818)
• Tumor suppressive effect of scavenger receptor class A member 5 overexpression in colorectal cancer by regulating PI3K/AKT/mTOR pathway. (PMID:34417976)
• Highly Expressing SCARA5 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma. (PMID:35755171)
• SCARA5 induced ferroptosis to effect ESCC proliferation and metastasis by combining with Ferritin light chain. (PMID:36513999)
• SCARA5 as a downstream factor of PCAT29, inhibits proliferation, migration, and invasion of bladder cancer. (PMID:37315873)
• m[6]A-mediated upregulation of lncRNA RMRP boosts the progression of bladder cancer via epigenetically suppressing SCARA5. (PMID:37337726)
• Methylated tumor suppressor gene SCARA5 inhibits the proliferation, migration and invasion of nasopharyngeal carcinoma. (PMID:37554122)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	scara5	ENSDARG00000010425
mus_musculus	Scara5	ENSMUSG00000022032
rattus_norvegicus	Scara5	ENSRNOG00000014398

Paralogs (3): MARCO (ENSG00000019169), MSR1 (ENSG00000038945), COLEC12 (ENSG00000158270)

Protein

Protein identifiers

Scavenger receptor class A member 5 — Q6ZMJ2 (reviewed: Q6ZMJ2)

Alternative names: Scavenger receptor hlg

All UniProt accessions (1): Q6ZMJ2

UniProt curated annotations — full annotation on UniProt →

Function. Ferritin receptor that mediates non-transferrin-dependent delivery of iron. Mediates cellular uptake of ferritin-bound iron by stimulating ferritin endocytosis from the cell surface with consequent iron delivery within the cell. Delivery of iron to cells by ferritin is required for the development of specific cell types, suggesting the existence of cell type-specific mechanisms of iron traffic in organogenesis, which alternatively utilize transferrin or non-transferrin iron delivery pathways. Ferritin mediates iron uptake in capsule cells of the developing kidney. Preferentially binds ferritin light chain (FTL) compared to heavy chain (FTH1).

Subunit / interactions. Homotrimer.

Subcellular location. Cell membrane.

Similarity. Belongs to the SCARA5 family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q6ZMJ2-1	1	yes
Q6ZMJ2-2	2
Q6ZMJ2-3	3
Q6ZMJ2-4	4

RefSeq proteins (4): NP_001400130, NP_001400131, NP_001400132, NP_776194* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001190	SRCR	Domain
IPR008160	Collagen	Repeat
IPR034726	SCARA5	Family
IPR036772	SRCR-like_dom_sf	Homologous_superfamily

Pfam: PF00530, PF01391

UniProt features (40 total): glycosylation site 6, strand 6, sequence conflict 5, splice variant 4, compositionally biased region 3, disulfide bond 3, helix 3, topological domain 2, sequence variant 2, domain 2, chain 1, transmembrane region 1, region of interest 1, coiled-coil region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
7C00	X-RAY DIFFRACTION	1.7

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6ZMJ2-F1	72.38	0.30

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (3): 418–482, 431–492, 462–472

Glycosylation sites (6): 102, 134, 193, 231, 254, 397

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-3000480	Scavenging by Class A Receptors
R-HSA-2173782	Binding and Uptake of Ligands by Scavenger Receptors
R-HSA-5653656	Vesicle-mediated transport

MSigDB gene sets: 116 (showing top): GOBP_TRANSITION_METAL_ION_TRANSPORT, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_INTRACELLULAR_IRON_ION_HOMEOSTASIS, GOCC_CELL_SURFACE, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_IRON_ION_TRANSPORT, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_PROTEIN_TRIMERIZATION, chr8p21, WONG_ENDMETRIUM_CANCER_DN, ODONNELL_TARGETS_OF_MYC_AND_TFRC_UP, MCBRYAN_PUBERTAL_BREAST_5_6WK_UP, GOBP_CELLULAR_RESPONSE_TO_HEAT, GOBP_RESPONSE_TO_ABIOTIC_STIMULUS, AACTTT_UNKNOWN

GO Biological Process (7): intracellular iron ion homeostasis (GO:0006879), endocytosis (GO:0006897), cellular response to heat (GO:0034605), iron ion transmembrane transport (GO:0034755), protein homotrimerization (GO:0070207), monoatomic ion transport (GO:0006811), iron ion transport (GO:0006826)

GO Molecular Function (2): ferritin receptor activity (GO:0070287), protein binding (GO:0005515)

GO Cellular Component (3): plasma membrane (GO:0005886), cell surface (GO:0009986), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Binding and Uptake of Ligands by Scavenger Receptors	1
Vesicle-mediated transport	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
intracellular monoatomic cation homeostasis	1
inorganic ion homeostasis	1
vesicle budding from membrane	1
membrane invagination	1
vesicle-mediated transport	1
import into cell	1
response to heat	1
cellular response to stress	1
iron ion transport	1
monoatomic cation transmembrane transport	1
protein homooligomerization	1
protein trimerization	1
transport	1
transition metal ion transport	1
cargo receptor activity	1
binding	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1396 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SCARA5	FTL	P02792	751
SCARA5	STAB2	Q8WWQ8	686
SCARA5	VTN	P01141	587
SCARA5	TC2N	Q8N9U0	581
SCARA5	TFRC	P02786	568
SCARA5	FTH1	P02794	521
SCARA5	LIX1	Q8N485	516
SCARA5	STXBP5	Q5T5C0	513
SCARA5	FGF2	P09038	481
SCARA5	PAMR1	Q6UXH9	457
SCARA5	CLEC4M	Q9H2X3	447
SCARA5	SOX2	P48431	446
SCARA5	POU5F1	P31359	441
SCARA5	BMP4	P12644	407
SCARA5	KLF4	P78338	405

IntAct

4 interactions, top by confidence:

A	B	Type	Score
CAND1	GTPBP10	psi-mi:“MI:0914”(association)	0.350
	TMEM223	psi-mi:“MI:0914”(association)	0.350
SCARA5	COLGALT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (29): HS3ST2 (Affinity Capture-MS), COLGALT2 (Affinity Capture-MS), SCARA5 (Biochemical Activity), SCARA5 (Two-hybrid), SCARA5 (Two-hybrid), SCARA5 (Two-hybrid), SCARA5 (Two-hybrid), SCARA5 (Two-hybrid), SCARA5 (Two-hybrid), SCARA5 (Two-hybrid), SCARA5 (Two-hybrid), SCARA5 (Two-hybrid), TMEM208 (Two-hybrid), RNF151 (Two-hybrid), C1QL4 (Two-hybrid)

ESM2 similar proteins: A2AV25, A5PJQ2, A5PMY6, A6H6E2, B7ZNG0, O00548, O35764, O43278, O70340, O95502, P21757, P21758, P30204, P47970, P47971, P47972, P48759, P58660, P59900, P97738, Q05585, Q15818, Q24K15, Q2M1P5, Q5RFW0, Q61483, Q62443, Q6AZY7, Q6MG84, Q6ZMJ2, Q86VZ4, Q8BJS4, Q8C850, Q8CB67, Q8K299, Q8N539, Q8NI99, Q8R0Z6, Q95LU3, Q96NZ8

Diamond homologs: A1L0T3, A1L1V4, A1L4H1, A5PJQ2, A6H737, A7E3W2, B4F6N6, B5DF27, B8A4W9, E1C3U7, F1QQC3, F1RD85, F7J220, G3V801, M9NDE3, O08762, O43866, O70513, P21757, P21758, P30203, P30204, P30205, P56730, P58022, P58215, P70117, P85521, Q05585, Q07797, Q08380, Q08B63, Q14DK5, Q24JV9, Q2VL90, Q2VLG4, Q2VLG6, Q2VLH6, Q4A3R3, Q4G0T1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

83 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	77
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1546 predictions. Top by Δscore:

Variant	Effect	Δscore
8:27879563:CCTTA:C	donor_loss	1.0000
8:27879564:CTTA:C	donor_loss	1.0000
8:27879565:TTA:T	donor_loss	1.0000
8:27879566:TA:T	donor_loss	1.0000
8:27879567:A:T	donor_loss	1.0000
8:27904776:A:AC	donor_gain	1.0000
8:27904777:C:CC	donor_gain	1.0000
8:27909657:CATTA:C	donor_loss	1.0000
8:27909659:TTACC:T	donor_loss	1.0000
8:27909660:TA:T	donor_loss	1.0000
8:27909661:A:AT	donor_loss	1.0000
8:27909662:CCTC:C	donor_loss	1.0000
8:27909742:CC:C	acceptor_gain	1.0000
8:27909742:CCCTG:C	acceptor_loss	1.0000
8:27909743:CC:C	acceptor_gain	1.0000
8:27909744:C:CC	acceptor_gain	1.0000
8:27909744:C:CG	acceptor_loss	1.0000
8:27909745:T:G	acceptor_loss	1.0000
8:27966408:TCTTA:T	donor_loss	1.0000
8:27966409:CTTAC:C	donor_loss	1.0000
8:27966410:TTA:T	donor_loss	1.0000
8:27966411:TACCT:T	donor_loss	1.0000
8:27966412:A:AG	donor_loss	1.0000
8:27966413:C:A	donor_loss	1.0000
8:27966413:CCTG:C	donor_gain	1.0000
8:27966541:ACC:A	acceptor_loss	1.0000
8:27966542:CCT:C	acceptor_loss	1.0000
8:27966543:C:CG	acceptor_loss	1.0000
8:27966544:T:C	acceptor_loss	1.0000
8:27987500:TCACC:T	donor_loss	1.0000

AlphaMissense

3189 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:27871991:C:A	W477C	0.999
8:27871991:C:G	W477C	0.999
8:27879654:C:A	W422C	0.999
8:27879654:C:G	W422C	0.999
8:27879678:C:A	W414C	0.999
8:27879678:C:G	W414C	0.999
8:27872037:C:G	C462S	0.998
8:27872038:A:T	C462S	0.998
8:27879576:G:C	F448L	0.998
8:27879576:G:T	F448L	0.998
8:27879578:A:G	F448L	0.998
8:27879667:C:T	C418Y	0.998
8:27871977:C:G	C482S	0.997
8:27871978:A:T	C482S	0.997
8:27879627:G:C	C431W	0.997
8:27879628:C:G	C431S	0.997
8:27879629:A:T	C431S	0.997
8:27879656:A:G	W422R	0.997
8:27879656:A:T	W422R	0.997
8:27879666:A:C	C418W	0.997
8:27871947:C:G	C492S	0.996
8:27871948:A:T	C492S	0.996
8:27871963:C:G	D487H	0.996
8:27871977:C:T	C482Y	0.996
8:27872007:C:G	C472S	0.996
8:27872008:A:T	C472S	0.996
8:27872032:C:A	G464C	0.996
8:27872037:C:T	C462Y	0.996
8:27872038:A:G	C462R	0.996
8:27872049:T:A	D458V	0.996

dbSNP variants (sampled 300 via entrez): RS1000008064 (8:27986918 G>A), RS1000056635 (8:27979251 A>C), RS1000058409 (8:27984742 T>G), RS1000071709 (8:27879830 T>G), RS1000193685 (8:27946880 C>T), RS1000297764 (8:27978857 C>T), RS1000298368 (8:27974070 G>A), RS1000405147 (8:27935491 C>T), RS1000424458 (8:27897105 AAAG>A), RS1000443968 (8:27871829 G>A), RS1000448095 (8:27947363 T>C), RS1000454257 (8:27908497 G>A,C), RS1000465785 (8:27882996 A>G), RS1000467982 (8:27941627 T>A), RS1000496945 (8:27882863 G>T)

Disease associations

OMIM: gene MIM:611306 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

16 associations (top):

Study	Trait	p-value
GCST002007_6	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)	3.000000e-06
GCST003210_7	Low vWF levels	3.000000e-07
GCST007445_16	Factor VIII levels	3.000000e-17
GCST007445_24	Factor VIII levels	3.000000e-10
GCST007445_33	Factor VIII levels	7.000000e-21
GCST007445_4	Factor VIII levels	5.000000e-16
GCST007445_45	Factor VIII levels	1.000000e-19
GCST007445_52	Factor VIII levels	1.000000e-19
GCST007445_60	Factor VIII levels	6.000000e-10
GCST007446_36	vWF levels	6.000000e-27
GCST007446_45	vWF levels	4.000000e-08
GCST007446_51	vWF levels	5.000000e-08
GCST007446_76	vWF levels	9.000000e-28
GCST007623_5	Lack of premeditation	8.000000e-07
GCST009030_8	Venous thromboembolism	2.000000e-09
GCST009442_2	Age-related cognitive decline (executive function) (slope of z-scores)	2.000000e-06

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004630	factor VIII measurement
EFO:0006946	behavioural disinhibition measurement
EFO:0007710	cognitive decline measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases methylation	2
Dexamethasone	increases expression, affects cotreatment	2
Valproic Acid	increases expression, affects expression	2
bisphenol A	affects cotreatment, decreases methylation, affects methylation	1
deoxynivalenol	decreases expression	1
1,6-diaminohexane	increases abundance	1
sodium arsenite	increases expression	1
benzo(e)pyrene	affects methylation	1
abrine	decreases expression	1
bisphenol S	decreases expression	1
Decitabine	affects expression	1
Fulvestrant	decreases methylation, affects cotreatment	1
Acetaminophen	decreases expression	1
Arsenic	affects methylation	1
Cisplatin	affects expression	1
Doxorubicin	decreases expression	1
Indomethacin	affects cotreatment, increases expression	1
Methapyrilene	affects methylation	1
Silicon Dioxide	decreases expression	1
Dronabinol	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Aflatoxin B1	affects methylation	1
Particulate Matter	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.